In the phase III clinical trial PALOMA-3, the capacity of plabociclib was evaluated, in association with fulvestrant, to improve the outcome of breast cancer patients with ER-positive/HER2-negative disease under progression after previous endocrine therapy [354]. Here, ESR1 is linked to breast carcinoma.